On Tuesday, in the course of current trade, Shares of Time Warner Cable Inc. (NYSE:TWC), dropped -0.57%, and is now trading at $179.26.
Time Warner Cable, declared that Executive Vice President and Chief Financial Officer Arthur Minson will leave the company, effective recently. He will remain as an advisor to the company until the Charter transaction closes. Serving as acting co-CFOs in his place will be William F. Osbourn, Jr., who presently serves as Senior Vice President-Controller and Chief Accounting Officer, and Matthew Siegel, who presently serves as Senior Vice President and Treasurer.
Mr. Minson will join WeWork as President and Chief Operating Officer. WeWork is a privately-held company that provides more than 25,000 members across the globe with space, community, and services through physical and virtual offerings. Based in New York City, WeWork presently has 42 physical locations in fifteen cities and four countries around the world.
Time Warner Cable Inc., together with its auxiliaries, provides video, high-speed data, and voice services in the United States. It operates in three segments: Residential Services, Business Services, and Other Operations.
Shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI), during its Tuesday’s current trading session fell -3.04%, and is now trading at $2.23.
OncoGenex Pharmaceuticals, declared that results from an exploratory analysis of the Phase 2 Borealis-1™ trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy contrast to chemotherapy alone. Patients in the trial with a Karnofsky Performance Status (KPS) of 80 percent or less, a common indicator of poor prognosis, practiced a 50 percent reduction in risk of death with the addition of apatorsen therapy (OS HR = 0.50). These results were presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago .
Borealis-1 was an international, randomized, placebo-controlled trial that evaluated the effect of apatorsen when added to first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. The trial enrolled about 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not formerly received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy. Patients were randomized to receive standard chemotherapy (gemcitabine/cisplatin) in combination with apatorsen at two dose levels (600mg and 1000mg) or gemcitabine/cisplatin plus placebo. The primary endpoint of the trial was overall survival. Secondary endpoints measured disease response in addition to safety of each of the two doses of apatorsen.
Exploratory analysis of study results showed that survival outcome was influenced by the following prognostic risk factors: KPS, liver involvement, low hemoglobin and high alkaline phosphatase. Patients who had these poor prognostic features benefited most from 600mg apatorsen therapy. Median overall survival in the poor prognostic group was 11.9 months with 600mg apatorsen + gemcitabine/cisplatin contrast to 9 months with gemcitabine/cisplatin alone (OS HR = .77). Importantly, 33 percent of patients in the trial had a KPS less than or equal to 80 percent, which was found to be the single most important risk factor for poor prognosis. These lower KPS, high-risk patients practiced a 50 percent reduction in risk of death (OS HR = 0.50) when 600mg apatorsen was added to chemotherapy.
Overall treatment was well tolerated. Most common Grade ≥3 adverse events (AEs) were neutropenia, anemia, thrombocytopenia and hypertension. Frequency of ≥3 Grade toxicities were: 89 percent (GC), 93 percent (GC+A 600) and 95 percent (GC+A 1000). GC+A 1000 had a higher treatment discontinuation rate due to AEs.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients.
Finally, Celladon Corporation (NASDAQ:CLDN), lost -1.08% Tuesday.
Celladon Corporation, declared that its Board of Directors has unanimously approved a planned plan following which the Company will right away commence a process to seek an acquisition or partnership. The Company also declared that it has retained Wedbush PacGrow Healthcare as its exclusive financial advisor.
The Board also unanimously approved a leadership succession plan, following which Paul Cleveland has been promoted to Chief Executive Officer of Celladon and designated to its Board of Directors, effective right away. Krisztina Zsebo, Ph.D, who had been Celladon’s Chief Executive Officer, has resigned from the Company and its Board of Directors. Following his vote in favor of these decisions, Patrick Y. Yang, Ph.D., also resigned from the Board of Directors. In addition, Andrew Jackson, formerly the Company’s Corporate Controller, was named Chief Financial Officer.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
